Mineralys Therapeutics Inc MLYS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Trading Information
- Previous Close Price
- $15.24
- Day Range
- $14.91–15.65
- 52-Week Range
- $14.91–47.65
- Bid/Ask
- $15.00 / $17.49
- Shares Outstanding
- 88.56M
- Market Cap
- $1.36B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 76
- Website
- https://mineralystx.com
Valuation
Metric | MLYS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.69 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | MLYS |
|---|---|
Quick Ratio | 11.77 |
Current Ratio | 11.83 |
Interest Coverage | — |
Quick Ratio
MLYS
Profitability
Metric | MLYS |
|---|---|
Return on Assets (Normalized) | −53.37% |
Return on Equity (Normalized) | −58.80% |
Return on Invested Capital (Normalized) | −60.16% |
Return on Assets
MLYS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|F@CQ<v! | LOCK|@xh%k | $139B | |||
| Moderna Inc MRNA | LOCK|BRYjc< | LOCK|g> | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|p>$G^&T | LOCK|!FfDx | $94B | |||
| argenx SE ADR ARGX | LOCK|@<$c^q | LOCK|C&B | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|V?B#MT | LOCK|>ts | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Mcs$Qwnl | LOCK|CMvDf | $30B | |||
| Incyte Corp INCY | LOCK|@B%ds$h | LOCK|L$% | $24B | |||
| BioNTech SE ADR BNTX | LOCK|@v@$#!# | LOCK|%@ | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|>bF##? | LOCK|R#NJ< | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|wN#w<y | LOCK|!< | $15B |
United States